Anbio Biotechnology Class A Ordinary Shares (NNNN) Price/FCF Ratio: History & Chart

Anbio Biotechnology Class A Ordinary Shares(NNNN)

Medical - Instruments & Supplies · Frankfurt am Main, HE

$4.90+0.07 (+1.45%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.

Frankfurt am Main, HE

27 employees

www.anbio.com

Healthcare / Medical - Instruments & Supplies

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO: Michael Lau

View full financials

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Anbio Biotechnology Class A Ordinary Shares (NNNN)	$215.07M	N/A	N/A	N/A	N/A
Sionna Therapeutics, Inc. (SION)vs ›	$214.46M	N/A	N/A	N/A	N/A
Niagen Bioscience Inc (NAGE)vs ›	$214.24M	37.76	48.24	64.03	64.30
Prelude Therapeutics Incorporated (PRLD)vs ›	$216.91M	N/A	N/A	N/A	N/A
Keros Therapeutics, Inc. (KROS)vs ›	$218.30M	N/A	9.31	9.38	9.38
Lyell Immunopharma, Inc. (LYEL)vs ›	$210.98M	N/A	N/A	N/A	N/A
Entrada Therapeutics, Inc. (TRDA)vs ›	$210.41M	N/A	4.17	4.17	4.17
Compugen Ltd. (CGEN)vs ›	$209.91M	N/A	N/A	N/A	N/A
Profound Medical Corp. (PROF)vs ›	$220.93M	N/A	N/A	N/A	N/A
Electra Therapeutics Inc. (ETRA)vs ›	$208.31M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PRICE/FCF RATIO

TTM

Anbio Biotechnology Class A Ordinary Shares (NNNN)

$215.07M

N/A

Sionna Therapeutics, Inc. (SION)vs ›

$214.46M

N/A

Niagen Bioscience Inc (NAGE)vs ›

$214.24M